Nintedanib and Symptoms of Fibrotic Lung Disease: a Glimmer of Hope for Patients Living with Pulmonary Fibrosis

Overview

Journal Eur Respir J

Specialty Pulmonary Medicine

Date 2024 Feb 1

PMID 38302183

Authors

Anna J Podolanczuk

Kerri I Aronson

Affiliations

Soon will be listed here.

References

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

Raghu G, Remy-Jardin M, Richeldi L, Thomson C, Inoue Y, Johkoh T . Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022; 205(9):e18-e47. PMC: 9851481. DOI: 10.1164/rccm.202202-0399ST. View

Noble P, Albera C, Bradford W, Costabel U, Glassberg M, Kardatzke D . Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377(9779):1760-9. DOI: 10.1016/S0140-6736(11)60405-4. View

Swigris J, Andrae D, Churney T, Johnson N, Scholand M, White E . Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. Am J Respir Crit Care Med. 2020; 202(12):1689-1697. PMC: 7737580. DOI: 10.1164/rccm.202002-0415OC. View

Swigris J, Esser D, Wilson H, Conoscenti C, Schmidt H, Stansen W . Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017; 49(1). DOI: 10.1183/13993003.01788-2016. View

Flaherty K, Wells A, Cottin V, Devaraj A, Walsh S, Inoue Y . Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381(18):1718-1727. DOI: 10.1056/NEJMoa1908681. View

Raghu G, Ghazipura M, Fleming T, Aronson K, Behr J, Brown K . Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the.... Am J Respir Crit Care Med. 2024; 209(6):647-669. DOI: 10.1164/rccm.202312-2213SO. View

Wijsenbeek M, Swigris J, Inoue Y, Kreuter M, Maher T, Suda T . Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis. Eur Respir J. 2023; 63(2). PMC: 10831140. DOI: 10.1183/13993003.00752-2023. View

Birring S, Bushnell D, Baldwin M, Mueller H, Male N, Rohr K . The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases. Eur Respir J. 2021; 59(6). PMC: 9160394. DOI: 10.1183/13993003.01790-2021. View

10.

Swigris J, Han M, Vij R, Noth I, Eisenstein E, Anstrom K . The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med. 2012; 106(10):1447-55. PMC: 3441137. DOI: 10.1016/j.rmed.2012.06.018. View

11.

Richeldi L, du Bois R, Raghu G, Azuma A, Brown K, Costabel U . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2071-82. DOI: 10.1056/NEJMoa1402584. View

12.

Aronson K, Martin-Schwarze A, Swigris J, Kolenic G, Krishnan J, Podolanczuk A . Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort. Am J Respir Crit Care Med. 2023; 208(2):188-195. PMC: 10395489. DOI: 10.1164/rccm.202208-1504OC. View